Cited by 116Advanced Drug Delivery SystemsNanoparticle-Based Drug DeliveryCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety

Nagpal, Kalpana, Singh, S.K., Mishra, D.N.·2013·International Journal of Biological Macromolecules

DOI 10.1016/j.ijbiomac.2013.04.024

Open this paper in CoChat — free account

Abstract

The study aims at formulation and optimization brain targeted nanoparticles (NP) of Rivastigmine (RT) to improve its therapeutic potential and to verify its safety profile. The NP were optimized using a two factor three level (3(2)) central composite design aiming to minimize particle size; maximize zeta potential and drug entrapment efficiency of NP. The optimized formulation (cRTNP) was evaluated using in vitro drug release study; in vivo behavioral, and biochemical and maximum tolerated dose (MTD) study. The optimized formulation evidenced a significant reversal of scopolamine-induced amnesia by Tween 80(®) coated nanoparticles as compared to both pure RT as well as uncoated nanoparticles. The MTD of RT was increased by 10% by formulating them as cRTNP. Thus, formulation of RT as cRTNP improved the therapeutic and safety profile of RT.

Integrity signals

Registry

Crossref · 10.1016/j.ijbiomac.2013.04.024

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

International Journal of Nanomedicine
(2020) · International Journal of Nanomedicine · doi:10.2147/ijn · Cited by 2,760
Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse
Irwin, S. (1968) · Psychopharmacology · doi:10.1007/bf00401402 · Cited by 1,240
Iranian Journal of Pharmaceutical Research
(2022) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr · Cited by 1,229
Blood–brain barrier delivery
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Chitosan Nanoparticles: A Promising System in Novel Drug Delivery
Nagpal, K., Singh, S. K., & Mishra, D. N. (2010) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.58.1423 · Cited by 661
Self-citation
Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones
Zensi, A., Begley, D., Pontikis, C., Legros, C., Mihoreanu, L., Wagner, S., Büchel, C., von Briesen, H., & Kreuter, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.002 · Cited by 438
New Acetylcholinesterase Inhibitors for Alzheimer's Disease
Mehta, M., Adem, A., & Sabbagh, M. N. (2011) · International Journal of Alzheimer s Disease · doi:10.1155/2012/728983 · Cited by 436
Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting
Fazil, M., Md, S., Haque, S., Kumar, M., Baboota, S., Sahni, J. K., & Ali, J. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.013 · Cited by 379
The Use of Surfactants to Enhance the Permeability of Peptides Through Caco-2 Cells by Inhibition of an Apically Polarized Efflux System
Nerurkar, M. M., Burton, P. S., & Borchardt, R. T. (1996) · Pharmaceutical Research · doi:10.1023/a:1016033702220 · Cited by 287
Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier Model
Wagner, S., Zensi, A., Wien, S., Tschickardt, S., Maier, W., Vogel, T., Worek, F., Pietrzik, C. U., Kreuter, J., & von Briesen, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032568 · Cited by 265

Show all 32 references

Research works printed but not linked: 4

Chhillar, 2012, Fundamental and Clinical Pharmacology
Nagpal, 2012, Inventi Rapid: NDDS, 1
da Volta Soares, 2011, International Journal of Nanomedicine, 6, 227
Tian, 2011, International Journal of Nanomedicine, 6, 445

Sorted by citations

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Chitosan in nasal delivery systems for therapeutic drugs
Casettari, L., & Illum, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.003 · Cited by 448
Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential Toxicity
Elnaggar, Y. S. R., Etman, S. M., Abdelmonsif, D. A., & Abdallah, O. Y. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24557 · Cited by 333
The Link between Oxidative Stress, Mitochondrial Dysfunction and Neuroinflammation in the Pathophysiology of Alzheimer’s Disease: Therapeutic Implications and Future Perspectives
Jurcău, M. C., Andronie-Cioara, F. L., Jurcău, A., Marcu, F., Ţiț, D. M., Pașcalău, N., & Nistor-Cseppentö, D. C. (2022) · Antioxidants · doi:10.3390/antiox11112167 · Cited by 226
Interests of chitosan nanoparticles ionically cross-linked with tripolyphosphate for biomedical applications
Bugnicourt, L., & Ladavière, C. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.06.002 · Cited by 202
Potential of Chitosan and Its Derivatives for Biomedical Applications in the Central Nervous System
Ojeda-Hernández, D. D., Canales-Aguirre, A. A., Matías‐Guiu, J., Gómez‐Pinedo, U., & Mateos‐Díaz, J. C. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00389 · Cited by 175
Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters
Cunha, S., Costa, C. P., Loureiro, J. A., Alves, J., Peixoto, A. F. R. O., Forbes, B., Lobo, J. M. S., & Silva, A. C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070599 · Cited by 156
Ursolic acid liposomes with chitosan modification: Promising antitumor drug delivery and efficacy
Wang, M., Zhao, T., Liu, Y., Wang, Q., Xing, S., Li, L., Wang, L., Liu, L., & Gao, D. (2016) · Materials Science and Engineering C · doi:10.1016/j.msec.2016.11.014 · Cited by 136
Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: Formulation, optimization and in vivo characterization
Rajput, A., & Butani, S. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.01.040 · Cited by 114
Overcoming the Blood-Brain Barrier: Functionalised Chitosan Nanocarriers
Caprifico, A. E., Foot, P. J. S., Polycarpou, E., & Calabrese, G. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111013 · Cited by 113
Chitosan-Based Nanocarriers for Nose to Brain Delivery
Aderibigbe, B. A., & Naki, T. (2019) · Applied Sciences · doi:10.3390/app9112219 · Cited by 105
Nanoparticle technology for treatment of Parkinson’s disease: The role of surface phenomena in reaching the brain
Leyva-Gómez, G., Cortés, H., Magaña, J. J., Leyva-García, N., Quintanar-Guerrero, D., & Florán, B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.009 · Cited by 102
PREPARATION OF CHITOSAN-TPP NANOPARTICLES: THE INFLUENCE OF CHITOSAN POLYMERIC PROPERTIES AND FORMULATION VARIABLES
Al‐Nemrawi, N. K., Alsharif, S. S. M., & Dave, R. H. (2018) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2018v10i5.26375 · Cited by 97
Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer’s Disease
Manek, E., Darvas, F., & Petroianu, G. A. (2020) · Molecules · doi:10.3390/molecules25204866 · Cited by 97
Optimize the parameters for the synthesis by the ionic gelation technique, purification, and freeze-drying of chitosan-sodium tripolyphosphate nanoparticles for biomedical purposes
Gutiérrez-Ruíz, S. C., Cortés, H., González‐Torres, M., Almarhoon, Z. M., Gürer, E. S., Sharifi‐Rad, J., & Leyva‐Gómez, G. (2024) · Journal of Biological Engineering · doi:10.1186/s13036-024-00403-w · Cited by 94
Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform
Pinto, M., Silva, V., Barreiro, S., Silva, R. V. D. S., Remião, F., Borges, F., & Fernandes, C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101658 · Cited by 97
Novel polydatin-loaded chitosan nanoparticles for safe and efficient type 2 diabetes therapy: In silico, in vitro and in vivo approaches
Abdel‐Moneim, A., El‐Shahawy, A. A. G., Yousef, A. I., El-Twab, S. M. A., Elden, Z. E., & Taha, M. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.11.031 · Cited by 86
Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate
Simon, A., Amaro, M. I., Cabral, L. M., Healy, A. M., & de Sousa, V. P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.01.066 · Cited by 84
In situ nanostructured hydrogel of resveratrol for brain targeting: in vitro-in vivo characterization
Rajput, A., Bariya, A. H., Allam, A. A., Othman, S. I., & Butani, S. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0540-6 · Cited by 83
Green synthesis of hydrolyzed starch–chitosan nano-composite as drug delivery system to gram negative bacteria
Shehabeldine, A. M., & Hasanin, M. S. (2019) · Environmental Nanotechnology Monitoring & Management · doi:10.1016/j.enmm.2019.100252 · Cited by 76
Optimization of rivastigmine nanoemulsion for enhanced brain delivery: In-vivo and toxicity evaluation
Haider, M. F., Khan, S., Gaba, B., Alam, T., Baboota, S., Ali, J., & Ali, A. (2018) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2018.01.123 · Cited by 68
Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease
Lauzon, M.-A., Daviau, A., Marcos, B., & Faucheux, N. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.024 · Cited by 66
The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders
Ngowi, E. E., Wang, Y., Qian, L., Helmy, Y. A. S. H., Anyomi, B. K., Li, T., Zheng, M., Jiang, E., Duan, S., Wei, J., et al. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.629832 · Cited by 68
Ellagic acid-loaded, tween 80-coated, chitosan nanoparticles as a promising therapeutic approach against breast cancer: In-vitro and in-vivo study
Kaur, H., Ghosh, S., Kumar, P., Basu, B., & Nagpal, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119927 · Cited by 59
Self-citation
Advances in Nanomedicine for the Treatment of Alzheimer’s and Parkinson’s Diseases
Hernando, S., Gartziandia, O., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0019 · Cited by 48
Quality-by-design driven analytical method (AQbD) development and validation of HPLC–UV technique to quantify rivastigmine hydrogen tartrate in lipidic nanocarriers: Forced degradation, and assessment of drug content and in vitro release studies
Salwa, & Kumar, L. (2023) · Microchemical Journal · doi:10.1016/j.microc.2023.108944 · Cited by 47
Flavonoid-Based Nanomedicines in Alzheimer’s Disease Therapeutics: Promises Made, a Long Way To Go
Prasanna, P., & Upadhyay, A. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00224 · Cited by 48
Nanomedicines in the Management of Alzheimer’s Disease: Current View and Future Prospects
Chopra, H., Bibi, S., Singh, I., Kamal, M. A., Islam, F., Alhumaydhi, F. A., Emran, T. B., & Cavalu, S. D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879114 · Cited by 48
A review of chitosan-based nanocarriers as drug delivery systems for brain diseases: Critical challenges, outlooks and promises
Khodaverdi, K., Bakhshi, A., Mozafari, M. R., & Naghib, S. M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134962 · Cited by 45
Polydatin-loaded chitosan nanoparticles ameliorates early diabetic nephropathy by attenuating oxidative stress and inflammatory responses in streptozotocin-induced diabetic rat
El-Hameed, A. M. A. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00699-7 · Cited by 43
Synthesis, characterization and evaluation of antioxidant properties of catechin hydrate nanoparticles
Kaur, R., Rajput, R., Nag, P., Kumar, S., Rachana, R., & Singh, M. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.04.030 · Cited by 40
Intranasal administration of brain-targeted HP-β-CD/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia
Liu, S., & Ho, P. C. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12797 · Cited by 39
The Effect of Cannabidiol Coated by Nano-Chitosan on Learning and Memory, Hippocampal CB1 and CB2 Levels, and Amyloid Plaques in an Alzheimer’s Disease Rat Model
Amini, M., & Abdolmaleki, Z. (2021) · Neuropsychobiology · doi:10.1159/000519534 · Cited by 37
Natural biomaterials in brain repair: A focus on collagen
Uçar, B. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105033 · Cited by 34
Characterization of alginate/chitosan-based nanoparticles and mathematical modeling of their SpBMP-9 release inducing neuronal differentiation of human SH-SY5Y cells
Lauzon, M.-A., Marcos, B., & Faucheux, N. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.11.075 · Cited by 31
Significance of Algal Polymer in Designing Amphotericin B Nanoparticles
Bhatia, S., Kumar, V., Sharma, K., Nagpal, K., & Bera, T. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/564573 · Cited by 27
Self-citation
Synthesis of a Rivastigmine and Insulin Combinational Mucoadhesive Nanoparticle for Intranasal Delivery
Jamshidnejad-Tosaramandani, T., Kashanian, S., Karimi, I., & Schiöth, H. B. (2024) · Polymers · doi:10.3390/polym16040510 · Cited by 28
Hepatoprotective Effects of Polydatin-Loaded Chitosan Nanoparticles in Diabetic Rats: Modulation of Glucose Metabolism, Oxidative Stress, and Inflammation Biomarkers
El-Hameed, A. M. A., Yousef, A. I., El-Twab, S. M. A., El‐Shahawy, A. A. G., & Abdel‐Moneim, A. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921020061 · Cited by 27
Single and Multitarget Systems for Drug Delivery and Detection: Up-to-Date Strategies for Brain Disorders
Grosso, C., Silva, A., Delerue-Matos, C. M., & Barroso, M. F. (2023) · Pharmaceuticals · doi:10.3390/ph16121721 · Cited by 26
Preparation and characterization of kanamycin-chitosan nanoparticles to improve the efficacy of antibacterial activity against nosocomial pathogens
Kumar, G. V., Su, C., & Velusamy, P. (2016) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2016.05.054 · Cited by 23
Neuroprotective effect of piracetam-loaded magnetic chitosan nanoparticles against thiacloprid-induced neurotoxicity in albino rats
Abomosallam, M., Hendam, B. M., Abdallah, A. A., Refaat, R., Elshatory, A., & El-Hak, H. N. G. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01151-x · Cited by 22
Formulation and characterization of chitosan nanoparticles loaded with neuroprotective flavonoid from Phyllanthus niruri Linn
Rajamanickam, G., & Manju, S. L. (2023) · Macromolecular Research · doi:10.1007/s13233-023-00114-z · Cited by 22
Carbohydrate Nanoparticles for Brain Delivery
Lalatsa, A., & Barbu, E. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.05.004 · Cited by 22
Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Garg, Y., Kapoor, D. N., Sharma, A. K., & Bhatia, A. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612828666211222163025 · Cited by 21
Polyphenols and Their Biogenic Nano‐Formulations Targeting BACE1 as Anti‐Amyloid Therapies; Meeting the Challenges of Bioavailability, Safety, and Specificity for the Treatment of Alzheimer's Disease
Elawad, M. A., Ayaz, M., Mosa, O. F., Usman, A., Hamdoon, A. A. E., Almawash, S., Salim, L. H. M., Ahmed, A., & Elkhalifa, M. E. M. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400525 · Cited by 20
Characterization and Mathematical Modeling of Alginate/Chitosan-Based Nanoparticles Releasing the Chemokine CXCL12 to Attract Glioblastoma Cells
Gascon, S., Solano, A. G., Kheir, W. E., Therriault, H., Berthelin, P., Cattier, B., Marcos, B., Virgilio, N., Paquette, B., Faucheux, N., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040356 · Cited by 20
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 20
Self-citation
Chitosan based nanocarriers as a promising tool in treatment and management of inflammatory diseases
Goyal, S., Thirumal, D., Rana, J., Gupta, A. K., Kumar, A., Babu, M. A., Kumar, P., & Sindhu, R. K. (2024) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2024.100442 · Cited by 22
Dual-Targeting Liposomes for Enhanced Anticancer Effect in Somatostatin Receptor II-Positive Tumor Model
Li, L., Wang, Q., Zhang, X., Luo, L., He, Y., Zhu, R., & Gao, D. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0115 · Cited by 18
Alternative methods for the pilot-scale production and characterization of chitosan nanoparticles
Alves, H. J., Gasparrini, L. J., Silva, F. E. B., Caciano, L., de Muñiz, G. I. B., Ballester, E. L. C., Cremonez, P. A., & Arantes, M. K. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-11343-5 · Cited by 17
Rivastigmine hydrogen tartrate polymorphs: Solid-state characterisation of transition and polymorphic conversion via milling
Amaro, M. I., Simon, A., Cabral, L. M., de Sousa, V. P., & Healy, A. M. (2015) · Solid State Sciences · doi:10.1016/j.solidstatesciences.2015.09.004 · Cited by 17
Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Bajić, V., Sudar-Milovanovic, E. M., Spremo‐Potparević, B., Živković, L., Milicevic, Z., Stanimirović, J., Bogdanović, N., & Isenović, E. R. (2015) · Current Pharmaceutical Analysis · doi:10.2174/1573412911666150611184740 · Cited by 16
Nanotechnology‐empowered therapeutics targeting neurodegenerative diseases
Wang, Z., Gonzalez, K. M., Cordova, L. E., & Lu, J. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1907 · Cited by 18
Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy
Liu, C., Wu, K.-Z., Gao, H. X., Li, J., & Xu, X. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s380550 · Cited by 15
An applied quantum-chemical model for genipin-crosslinked chitosan (GCS) nanocarrier
Nasrabadi, M., Morsali, A., & Beyramabadi, S. A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.10.013 · Cited by 15
Toxicological study of the Primaquine phosphate loaded chitosan nanoparticles in mice
Rajera, R., Nagpal, K., Singh, S. K., & Mishra, D. N. (2013) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2013.08.019 · Cited by 15
Self-citation
Chitosan Nanoparticles Alleviated the Adverse Effects of Sildenafil on the Oxidative Stress Markers and Antioxidant Enzyme Activities in Rats
Sheweita, S. A., Alian, D. M. E., Haroun, M., Nounou, M. I., Patel, A. A., & El-Khordagui, L. K. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/9944985 · Cited by 14
Alzheimer hastalığı tedavisinde nano boyutlu ilaç taşıyıcı sistemlerin kullanımı
GÜN, D. N. (2016) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.1501/eczfak_0000000579 · Cited by 14
The current advancements in chitosan nanoparticles in the management of non-surgical periodontitis treatment
Shamami, M. S., Ekhlaspour, M., Sulaiman, J. M. A., Kareem, R. A., Alsultany, N. M. A., Nasiri, K., & Shenasa, N. (2025) · Nanotoxicology · doi:10.1080/17435390.2025.2484002 · Cited by 11
Revolutionizing Neurological Therapies: The Multifaceted Potential of Zein-Based Nanoparticles for Brain-Targeted Drug Delivery
Narayan, S., Gupta, P. K., & Nagpal, K. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00062 · Cited by 12
Self-citation
Intranasal delivery of chitosan-based nanoparticles as an innovative way for management of neurodegenerative disorders: A comprehensive review of advanced strategies for CNS targeting
Ibrahim, R. M., Teaima, M. H. M., El-Nabarawi, M. A., & Badawi, N. M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105885 · Cited by 12
Polyphenol-conjugated polysaccharide nanoplatforms for enhanced therapeutic efficacy
Narayan, S., Nagpal, K., & Kumar, P. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2514714 · Cited by 11
Self-citation
In situ encapsulation of rivastigmine in TAT-functionalized P(MMA-co-AA) nanoparticles through miniemulsion polymerization
Mangia, L. H. R., Ferraz, H. C., de Souza, R. S., Pereira, M. C. D. S., & Pinto, J. C. (2021) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2021.126776 · Cited by 10
Formulation and Characterization of Propranolol Nanoparticles for Transmucosal Nasal Drug Delivery
Nag, P., Rajput, R., Dhaliwal, S., Kumar, S., Prajapat, D., & Singh, M. (2015) · Macromolecular Symposia · doi:10.1002/masy.201400051 · Cited by 9
Design and Development of Lomustine Loaded Chitosan Nanoparticles for Efficient Brain Targeting
Anand, A., Iyer, B. R., Ponnusamy, C., Pandiyan, R., & Sugumaran, A. (2020) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525718666200203112502 · Cited by 9
A Stability Indicating HPLC Assay Method for Analysis of Rivastigmine Hydrogen Tartrate in Dual-Ligand Nanoparticle Formulation Matrices and Cell Transport Medium
Huda, N. H., Gauri, B., Benson, H. A., & Chen, Y. (2018) · Journal of Analytical Methods in Chemistry · doi:10.1155/2018/1841937 · Cited by 9
Minocycline encapsulated chitosan nanoparticles for central antinociceptive activity
Nagpal, K., Singh, S. K., & Mishra, D. N. (2014) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2014.07.055 · Cited by 8
Self-citation
Nanotechnology Based Delivery Systems of Drugs Currently Used to Treat Alzheimer’s Disease
Choubdar, N., & Avizheh, S. (2019) · Nanoscience & Nanotechnology-Asia · doi:10.2174/2210681209666190228143636 · Cited by 7
Intranasal administration of in silico designed Rivastigmine mucoadhesive nanoparticles ameliorates scopolamine-induced Alzheimer’s symptoms in mice: Pharmacokinetic and pharmacodynamic evidences
Kalra, V., Silakari, O., & Tiwary, A. K. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125635 · Cited by 6
Polydatin nanoparticles attenuate oxidative stress and histopathological changes in streptozotocin model of diabetic nephropathy: targeting Nrf2/HO-1/NF-κβ signaling pathways
Abdul‐Hamid, M., Galaly, S. R., Mohamed, H. M., Mostafa, F., & Abdel‐Moneim, A. (2023) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-023-00441-1 · Cited by 6
Biopolymers as promising vehicles for drug delivery to the brain
Mythri, R. B., & Aishwarya, M. (2023) · Drug Metabolism Reviews · doi:10.1080/03602532.2023.2281855 · Cited by 6
Advances in Neurotherapeutic Delivery Technologies
Mr Pradeep, K. (2015) · OMICS International eBooks · doi:10.4172/978-1-63278-036-2-037 · Cited by 6
Acetylcholinesterase inhibitors and nanoparticles on Alzheimer’s disease: a review
Silva, S., Almeida, A. J., & Vale, N. (2021) · Journal of Nanoparticle Research · doi:10.1007/s11051-020-05118-9 · Cited by 6
Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer’s disease
Namdeo, P., Mathew, J., & Garg, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00004-6 · Cited by 5
Extravaganza of Nanobiotechnology in the Diagnosis and Treatment of Dementia Patients
Bhattacharya, S. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1385272827666221027103050 · Cited by 6
Rivastigmine
Ezzat, S. M., Salem, M. A., El Mahdy, N. M., & Ragab, M. F. (2021) · Naturally Occurring Chemicals Against Alzheimer's Disease · doi:10.1016/b978-0-12-819212-2.00007-4 · Cited by 4
Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment
Hernando, S., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-57696-1_3 · Cited by 4
Nanopolymer Chitosan in Cancer and Alzheimer Biomedical Application
Putri, A. D., Murti, B. T., Sabela, M. I., Kanchi, S., & Bisetty, K. (2017) · doi:10.1002/9781119364849.ch12 · Cited by 4
Tween 80-Modified Chitosan Nanoparticles via Ionotropic Gelation for Enhanced Brain Delivery of Chrysin and Improved Anxiolytic Efficacy in Preclinical Models
Dey, P., Narayan, S., & Nagpal, K. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00611 · Cited by 3
Self-citation
A Medico-Biological Approach to Chitosan Bionanocomposites
Khanna, N., Chatterji, T., Singh, S., & Khanna, N. (2023) · Biological and medical physics, biomedical engineering · doi:10.1007/978-981-19-9646-7_3 · Cited by 3
Self-citation
Chitosan-based nanoparticles for the treatment of neurological disorders
Enejiyon, S. O., Komolafe, L. I., Ahmad, N. H., Muhammad, F. E., Okoye, U. M., Oyewole, O. A., & Adetunji, C. O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13997-0.00014-x · Cited by 3
Polymeric nanoparticles as drug delivery systems for dementia
Esteruelas, G., Souto, E. B., Cano, A. C., Ettcheto, M., Espina, M., Camins, A., García, M. L., & Sánchez‐López, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824331-2.00006-6 · Cited by 3
Nanoengineering and nanotechnology for diagnosis and treatment of CNS and neurological diseases
Kumar, P., Dwivedi, A., Plaimas, K., Sagar, K., & Chauhan, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91182-5.00006-1 · Cited by 3
Polymeric nanosystems for neurological therapeutics
Noah, N. M., & Ndangili, P. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85656-0.00010-3 · Cited by 3
Nano chitosan anchored copper-ferrite: a smart magnetic nanocomposite agent for drug delivery
Adebayo, A. O., Alli, Y. A., Bamisaye, A., & Adewuyi, S. (2023) · Emergent Materials · doi:10.1007/s42247-023-00584-y · Cited by 3
Development and characterization of nanostructured lipid carriers for sustained rivastigmine delivery in Alzheimer's disease
Assaf, S. M., Almnayyes, A. I., Obaidat, R., & Maaroof, K. T. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107803 · Cited by 2
Brain-targeted mucoadhesive in situ gel incorporating quercetin-PEG conjugate and rivastigmine-loaded chitosan nanoparticles for Alzheimer's therapy
Aslam, S., Tulain, U. R., Zahid, F., Ali, Z., Erum, A., Alamri, A. H., Fatease, A. M. A., Amin, M., Wan, G., & Din, F. U. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151998 · Cited by 2
Signaling Pathways Triggering Therapeutical Potential of Marine-Derived Polysaccharides in Alzheimer’s Disease: A Recent Review
Kumar, D., Kondaveeti, S. B., Agrawal, M., Kumar, A., Awasthi, A., Mahmood, S., Singh, T. G., & Kumar, M. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05857-1 · Cited by 2
Curcumin‐loaded nanoparticle based on poloxamer188 for glioma treatment: Synthesis, characterization and in vitro evaluation
Hou, X., Xu, J., He, S., Bai, J., Guan, Y., Pan, X., Yang, J., Zhang, N., Yang, S., Hu, J., et al. (2023) · Polymers for Advanced Technologies · doi:10.1002/pat.6120 · Cited by 2
Nose-to-Brain Drug Delivery Strategies for the Treatment of Neurological Disorders
Prabakaran, A., Bhatane, D., & Alexander, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_17 · Cited by 2
Thyme oil-loaded chitosan microparticles: an antibacterial approach against pathogenic bacteria
Thakur, A., & Sharma, K. (2025) · 3 Biotech · doi:10.1007/s13205-025-04301-w · Cited by 2
Tuning three-dimensional nano-assembly in the mesoscale via bis(imino)pyridine molecular functionalization
Brisbin, R., Bartolo, M., Leveille, M. P., Rajan, A. K., Jahan, B., McCloskey, K. E., Gopinathan, A., Ghosh, S., & Baxter, R. D. (2022) · Scientific Reports · doi:10.1038/s41598-022-04851-6 · Cited by 2
Fabrication and optimization of verapamil-loaded PEGylated nanoparticles for management of traumatic brain injury: a comparative evaluation
Amin, O. M., Khalifa, M. K. A., El-Fattah, M. A. A., Allam, A., Aboutaleb, A. S., & Al‐Najjar, A. H. (2025) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2025.2592102 · Cited by 1
Enhancement of the Anti-Inflammatory Effect of Zingerone Using the Galactosylated Chitosan Nano Formula Against CCl4-Induced Hepatic Fibrosis: An In Vivo Study
Ismail, S. M., Eldin, Z. E., Elbakkay, M. H., Abdel‐Moneim, A., El‐Shahawy, A. A. G., & Zanaty, M. I. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10595-x · Cited by 1
Nanoparticulate systems for sustained delivery of paracrine factors
Arabi, L., Ho, J. Q., Javdani, N., Jones, S. M., Chen, I., Sharaf, M., Aieneravaie, M., Georgala, P., Sepand, M. R., Rafat, M., et al. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817434-0.00011-8 · Cited by 1
Biological nanodrugs for brain targeting
Jovčevska, I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90773-6.00028-2 · Cited by 1
Neuroprotection through nanotechnology
Kaur, J., Khan, F. D., & Naqvi, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00080-4 · Cited by 1
Nanotechnological Drug Delivery Strategies in Epilepsy
Esteruelas, G., Bonilla-Vidal, L., Ettcheto, M., Haro, I., Gomara, M. J., Souto, E. B., Espina, M., Camins, A., García, M. L., Sánchez‐López, E., et al. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_14 · Cited by 1
De novo fabrication of oral insulin-loaded chitosan/dextrin/pectin nanospheres and their antidiabetic efficacy in streptozotocin-induced diabetic rats
Mohammed, S. R., Abdel‐Moneim, A., Abdel-Reheim, E., Ramadan, H., Eldin, Z. E., El‐Shahawy, A. A. G., & Yousef, A. I. (2024) · Journal of Optoelectronic and Biomedical Materials · doi:10.15251/jobm.2024.162.73 · Cited by 1
Biomarker detection of Parkinson’s disease: therapy and treatment using nanomaterials
Nanda, R., Panda, P., & Mishra, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817923-9.00017-1 · Cited by 1

Authors: Nagpal, K., Singh, S. K., & Mishra, D. N.
Affiliations: Guru Jambheshwar University of Science and Technology (IN)
Corresponding author: Nagpal, Kalpana
ORCID: Nagpal, Kalpana
Singh, S.K.
Venue: International Journal of Biological Macromolecules
Publisher: Elsevier BV
Published: 2013-08
Volume: 59
Pages: 72-83
ISSN: 0141-8130 (ISSN-L)
DOI: 10.1016/j.ijbiomac.2013.04.024
OpenAlex: W2024268060
Cited by: 116
References: 32
Citations by year: 2026: 8 · 2025: 10 · 2024: 11 · 2023: 16 · 2022: 10 · 2021: 10 · 2020: 16 · 2019: 6 · 2018: 5 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 3 · 2013: 1
FWCI: 3.61
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: International Journal of Biological Macromolecules (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: rivastigmine, chitosan nanoparticles, brain drug delivery, central composite design, scopolamine-induced amnesia, maximum tolerated dose, encapsulation efficiency, zeta potential, particle size, in vitro drug release, Alzheimer's disease
MeSH terms: Rivastigmine, Amnesia, Animals, Behavior, Animal, Body Weight, Brain, Dose-Response Relationship, Drug, Drug Carriers, Drug Compounding, Drug Evaluation, Preclinical, Factor Analysis, Statistical, Male, Memory, Polysorbates, Scopolamine, Treatment Outcome, Neuroprotective Agents, Maze Learning, Chitosan, Phenylcarbamates, Mice, Rats, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks